# Therapeutic Dose Monitoring (TDM) of Tamoxifen

> **NCT05133674** · PHASE2 · UNKNOWN · sponsor: **Karolinska University Hospital** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Breast Tumors
- Cancer of Breast
- Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Tamoxifen 20 mg

## Key facts

- **NCT ID:** NCT05133674
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-04
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05133674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05133674, "Therapeutic Dose Monitoring (TDM) of Tamoxifen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05133674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*